BrightFocus Foundation

Alzheimer’s disease has long been linked to toxic brain proteins, but growing evidence suggests a certain immune cell may also play an important role.  BrightFocus Alzheimer’s Disease Research grant recipient Dr. Joshua Emmerson is studying how immune T cells may worsen brain damage — and whether blocking them could help protect neurons. Learn more. ↘️ brightfocus.org/news/can-targe…

We're hosting an interactive Macular Chat on March 25 where we'll answer your top questions about age-related macular degeneration (AMD). We’ll cover everything from the different types of AMD to nutrition, supplements, daily living tips, and current treatment options. Register now to join the conversation. bit.ly/4rxnNHr

More than 4 million Americans have glaucoma, and many don't know it until vision is already lost. 👁️ In our November Glaucoma Chat, Dr. Poonam Misra, a glaucoma specialist at Manhattan Eye, Ear & Throat Hospital, answered the questions people ask us the most, such as what causes glaucoma, effective treatment options, and whether diet, exercise, or stress actually affect your eye pressure. Read the full transcript or listen to the conversation: bit.ly/3ZO3cTQ. #Glaucoma #GlaucomaChat #Health

The buildup of lipid-rich waste products, called drusen, in the eye is an early sign of age-related macular degeneration (AMD). BrightFocus Macular Degeneration Research-funded scientist Neetu Kushwah, PhD, is studying how the malfunctioning of lipid processing in the eye drives inflammation and AMD. Her research focuses on a specific lipid-sensing receptor called RORa that could be a valuable new therapeutic target. Find out more: bit.ly/47FIbie #Science #Research #VisionLoss

On March 26, neurologist Dr. Sharon Cohen joins us to walk through the early signs of Alzheimer's, the conditions that can look like dementia but aren't, and how to have a productive conversation with your doctor. Bring your questions. Register to join live: bit.ly/4qhsHsO

Today's the day. Tune in live as Dr. Jeffrey Cummings walks through the evolving Alzheimer's treatment pipeline. In 2025, 182 clinical trials evaluated 138 experimental drugs, reflecting real momentum in how scientists understand the biology, genetics, and biomarkers driving this disease. Learn how that progress is translating into new medicines, devices, and prevention strategies. 🔴 WATCH LIVE TODAY at 1pm ET. ⬇️ youtube.com/live/6SyRYUnU7…

Family history is one of the strongest risk factors for glaucoma—having a parent, sibling, or child with the disease can increase your risk by up to 10 times. Dr. Inas Aboobakar of @MassEyeAndEar joins Glaucoma Chats to explain the role of genetics and family history in glaucoma, what and when to share with relatives, and how to encourage glaucoma eye exams. Register & ask your questions live: bit.ly/4u7l1Lh

“Every individual and their situation is absolutely different.” – Ellen Ladau Whether you manage your vision loss independently, lean on loved ones, or work with a professional, your experience is valid and unique. Our November Macular Chat explored the role of care partners in vision loss, with guests Ellen Ladau and Robin Saunders sharing real-world insights and advice. Listen to the full conversation: bit.ly/4cINeBW

New research is reshaping what scientists know about Alzheimer's disease and what they can do about it. In 2025, 182 clinical trials evaluated 138 experimental drugs, reflecting a field that has grown considerably more active as advances in genetics, biology, and biomarkers point researchers toward more promising targets. On March 5, Dr. Jeffrey Cummings will give us an inside look at where the Alzheimer's treatment pipeline stands today and what may be on the horizon. Register to join the conversation: bit.ly/4cNuYHz

From disease-modifying therapies and oral pills to non-pharmacological options, the Alzheimer’s treatment pipeline includes a wider range of approaches than ever before. Read about what’s to come in 2026 and beyond: bit.ly/4aMpGcS.

For decades, Alzheimer's disease treatment meant managing symptoms. That's changing. Leqembi and Kisunla are the first FDA-approved therapies to slow Alzheimer's progression. The evidence is clear: earlier intervention matters. People who begin treatment before significant cognitive or functional decline see the greatest benefit. Learn how these therapies work, who qualifies, and what the risks and benefits really look like. To watch the full episode or register to watch future episodes, visit: bit.ly/4awUuzt.

Over a decade ago, BrightFocus Foundation grant recipient, Dr. Ilyas Washington acted on an unconventional hunch that enriched vitamin A could stop toxic buildup in the eye, a hallmark of macular degeneration. His research led to an oral pill that is now in clinical trials showing promise for slowing vision loss in rare and age-related forms of macular degeneration. Early-stage research funding is how we turn scientific hunches into breakthroughs that preserve sight. Explore the research. ↘️ brightfocus.org/news/early-res…

🔴 LIVE TODAY 🔴 Dr. Manuel Amador from Genentech joins our Macular Chat at 1 p.m. ET to talk about treatments for wet age-related macular degeneration and how consistency can protect your vision. ↘️ Tune in now. bit.ly/4t3R8ey

New research is reshaping what scientists know about Alzheimer's. On March 5, Dr. Jeffrey Cummings joins BrightFocus Foundation to offer an inside look at where the Alzheimer's treatment pipeline stands today and what may be on the horizon.

For the more than 4 million Americans living with glaucoma, a diagnosis can feel overwhelming. For many, treatment has meant a daily lifelong regimen of eye drops. But that picture is changing. Dr. Mehul Nagarsheth breaks down how advances in laser therapy, sustained-release implants and minimally invasive surgery are offering people new ways to manage the disease. Full conversation at: bit.ly/4tYg5bR. 🎧

Early-stage age-related macular degeneration often has no symptoms. By the time people notice vision changes, the disease may have already progressed. That's why Paul, a stand-up comedian living with AMD, recommends comprehensive eye exams for everyone over 40, even if your vision seems fine. This #AMDAwarenessMonth, take action to protect your eyesight and get the facts: bit.ly/49L8K7n. #Health #MacularDegeneration #VisionLoss

🧬 LIVE today at 1 p.m. ET: Dr. Eric M. Reiman joins us to discuss APOE4, genetic testing, and what it means for your Alzheimer's risk. We'll also discuss treatments, potential side effects, and clinical research opportunities. Your questions welcome! ↘️ youtube.com/live/XDRd-MRpD…

Could we prevent Alzheimer's before memory loss begins? Dr. Joshua Grill explains how researchers are exploring early treatment to slow or stop brain changes associated with Alzheimer’s disease in people at higher risk. Learn more about this promising area of research ➡️ bit.ly/4k3QPMP.

Are you aware of the treatment options for age-related macular degeneration? Understanding your options is an essential part of managing AMD and protecting your remaining vision. Whether you've been recently diagnosed or are looking for the latest information on available treatments, having reliable, up-to-date resources matters. This #AMDAwarenessMonth, download our Treatments for Macular Degeneration fact sheet to learn about current treatments, what to expect, and questions to ask your eye doctor. brightfocus.org/resource/treat…

Did you know that staying on schedule with wet AMD treatment is one of the most powerful things you can do for your vision? Dr. Manuel Amador from Genentech is joining our February Macular Chat to talk about treatments, consistency, early detection, and more. Don't miss it. 🔗 Register now: bit.ly/40cMgq7